Immunosuppressive oligodeoxynucleotides (Sup ODNs) containing repetitive TTAGGG motifs reduce inflammation and, thus, may have an impact on inflammation-related tumor growth. In this study, we found a significant antiproliferative effect of Sup ODNs on the A549 non-small cell lung cancer (NSCLC) cell line compared to those treated with control ODNs (p<0.05). Sup-ODN-mediated G1 phase cell cycle arrest was achieved via inhibition of Akt and extracellular signal-regulated kinase 1/2 phosphorylation and the p15
Introduction
Lung cancer is the leading cause of cancer-related mortality in both men and women worldwide (1) . It is mainly classified into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). As compared to NSCLC chemotherapy, SCLC shows a better response towards radiotherapy and chemotherapy. Although the platinum-based doublet chemotherapy is the first-line standard chemotherapy for advanced disease, the response rate of NSCLC is only approximately 30%, resulting in 9 months overall survival (2) . The poor prognosis of lung cancer is mainly because of the characteristics of this tumor to metastasize to distant organs early in the course of the disease. These processes are mainly mediated by transmembrane receptors called integrins, which act as the bridge between the cytoskeleton and extracellular matrix proteins, and are essential elements of tumor invasion and metastasis formation (3) . Our previous study provided evidence that integrin-linked kinase, integrin β1, and the activated form of Akt are mutually associated with poor prognosis in NSCLC patients (4) . In addition, it is also known that extracellular signal-regulated kinase (ERK) signaling pathway is aberrantly activated in cancer, in particular by upstream activation by the epidermal growth factor receptor and the Ras small guanosine triphosphatases and then promotes proliferation, cell survival and metastasis (5, 6) .
Inflammatory processes are associated with the development and/or progression of cancer (7, 8) . Previous reports have suggested that treatment with anti-inflammatory agents may reduce host susceptibility to cancer development (7, 8) . Recent studies have shown that immunosuppressive oligodeoxynucleotides (Sup ODNs) containing repetitive TTAGGG motifs prevent inflammation, including arthritis, lupus nephritis, toxic shock, acute silicosis and inflammation-associated oncogenesis (9) (10) (11) (12) (13) (14) (15) (16) 
Materials and methods
ODNs and reagents. Phosphorothioate ODNs were purchased from Integrated DNA Technologies (IDT, Coralville, IA, USA). The sequence of Sup ODN was TTAGGGTTAGGGTTAG GGTTAGGG and control ODN was GCTAGATGTTAGCGT. Previous studies have shown that the effect of Sup ODNs was sequence-dependent but not length-dependent and that the length of the control ODNs did not affect activity (16). 5-Fluorouracil (5-FU) was purchased from MP Biomedicals (Irvine, CA, USA). Gemcitabine, paclitaxel, vinorelbine ditartrate (VNR), irinotecan hydrochloride trihydrate, carboplatin and cisplatin were purchased from Wako Pure Chemical Industries (Osaka, Japan).
Cell lines and culture. Non-small cell lung cancer cell line: A549 (p16-null, wild-type p53) cells were purchased from the American Type Culture Collection (Manassas, VA, USA) and maintained in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 1% (v/v) GlutaMAX (Invitrogen, Carlsbad, CA, USA), 1% (v/v) penicillin-streptomycin (Invitrogen), 10% (v/v) fetal bovine serum (Equitech-Bio, Ingram, TX, USA). Normal human bronchial epithelial (NHBE) cells were purchased from EIDIA (Tokyo, Japan) and maintained in Airway Epithelial Cell Growth Medium (PromoCell, Heidelberg, Germany). Single-cell suspensions were allowed to attach to the plate over 24 h in 6-or 96-well plates (Sumitomo, Osaka, Japan). Phosphorothioated ODNs were added to culture 1 h before administration of anticancer drugs.
Cell viability assays. Anticancer drugs and/or ODN-mediated cytotoxicity was assessed using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay as previously described (15) . Cells were seeded in 96-well plates at a density of 4,000 cells/well and allowed to adhere for 24 h. The cultures were then exposed to anticancer drug with/without Sup ODNs or control ODNs (0.1, 0.3, 1, 3, 10 and 30 µM) for 72 h, followed by MTT assay. Briefly, 100 µl medium containing MTT (Dojindo Laboratories, Osaka, Japan; 0.5 mg/ml) was added to the adherent cells for 2 h. Non-internalized MTT was then washed away and the cells lysed by the addition of 50 µl DMSO. This Western blot analysis. Cells were cultured with Sup ODNs or control ODNs (0.1, 0.3, 1, 3 and 10 µM) for 1, 3, 6, 12, 18 and 24 h, and then lysed in cold buffer containing 137 mM sodium chloride, 20 mM Tris, 1 mM EDTA, 50 mM sodium fluoride, 1% Triton X, protease inhibitor cocktail and phosphatase inhibitor cocktail (Sigma-Aldrich). Protein concentrations were determined using a BCA Protein Assay kit (Thermo Scientific, Rockford, IL, USA), and 10 µg whole cell extract was boiled for 5 min in sample buffer. The boiled samples were run on 4-12% gradient SDS-PAGE and transferred onto PVDF membranes. Immunoblots were probed with antibody specific to Akt (pan), phospho-Akt (Ser473), phospho-Akt (Thy308), ERK, phosphor-ERK1/2, cyclin-dependent kinase 4 (Cdk4), Cdk6, cyclin D1, p15 INK4b , p27 KIP1 , p21 (Cell Signaling Technology, Beverly, MA, USA), cyclin E (Invitrogen), Cdk2 (EMD Millipore Corporation, Billerica, MA, USA), p53 and retinoblastoma protein (pRb) (BD Pharmingen), followed by HRP-conjugated secondary antibody (Cell Signaling Technology). Signals were visualized using an enhanced chemiluminescence kit (GE Healthcare, Piscataway, NJ, USA). Blots were reprobed with anti-β-actin antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) to normalize for protein loading.
Statistical analysis. Statistical analyses were performed using GraphPad PRISM, version 5.01 (GraphPad Software, San Diego, CA, USA). Differences between groups were assessed using the t-test. All tests were two-sided; p-values of 0.05 were considered significant. The interaction between Sup ODNs and conventional anticancer drugs was analyzed by isobologram analysis using CalcuSyn software (Biosoft, Cambridge, UK) to determine whether the combination was additive or synergistic; a combination index (CI) <1.0 indicated a synergistic effect.
Results

Effect of Sup ODNs on proliferation of A549 NSCLC cell line.
A549 NSCLC cell line was cultured for 3 days with 0.1-30 µM Sup ODNs or control ODNs and evaluated for viability by MTT assay. There was a significant and dose-dependent reduction in viability of A549 cells treated with Sup ODNs when compared to control ODNs ( Fig. 1A; p<0.05). The mean 50% inhibitory concentration (IC 50 ) value for A549 cells was 2.5 µM. Normal human bronchial epithelial cells treated with high concentrations of Sup ODNs (10-30 µM) showed no significant reduction in viability compared to those treated with control ODNs or medium alone (Fig. 1B) .
Induction of G1 phase arrest via expression of p15
INK4b and p27 KIP1 . A549 cells were incubated with 3 µM Sup ODNs or control ODNs. The effect of this treatment on progression through the cell cycle was analyzed by flow cytometry (Fig. 2A) . Sup ODNs treatment led to ~20% increase in the number of cells in G0/G1 phase, whereas the frequency in S phase fell by 10-15% (Fig. 2B) . These findings are consistent with Sup ODNs inducing cell cycle arrest in the G1 phase.
Expression of cell cycle-related proteins was then analyzed by western blot analysis. Results showed that Sup ODNs increased expression of Cdk inhibitors including p15
INK4b and p27 KIP1 , therefore increased expression of cyclin E and reduced expression of Cdk2, cyclin D1 and retinoblastoma protein (pRb) phosphorylation in a dose-dependent manner (Fig. 3A) . As shown in Fig. 3B , these changes were found at significant level in cells treated with 3 µM Sup ODNs for 24 h by densitometric analysis of band intensities. These results were similar to previous reports of induced G0/G1 arrest via Cdk inhibitors including p21 and p27 KIP1 (17, 18) . In contrast, Sup ODNs did not increase expression of p53 and p21. Reduction of pRb phosphorylation is a key factor of G1 phase cell cycle arrest (19, 20) , therefore, these results demonstrated that Sup-ODN-mediated G1 phase of cell cycle arrest was achieved via the p15
INK4b and p27 KIP1 /pRb pathway. 
Effect of Sup ODNs on Akt and ERK1/2 phosphorylation.
To clarify the mechanism of action of Sup ODNs, the screening was performed by using a Human Phospho-Kinase Antibody Array (R&D Systems, Minneapolis, MN, USA). A549 cells was cultured for 16 h under serum-starved conditions and then treated with 3 µM Sup ODNs, or untreated for 1 h in normal medium. The expression of phosphorylated Akt and ERK1/2 was increased on untreated cells. In contrast, Sup ODNs reduced the expression of them (data not shown).
Confirmation of the effect of Sup ODNs on Akt and ERK1/2
phosphorylation. A549 NSCLC cell line was cultured for 16 h under serum-starved conditions to dephosphorylate Akt and ERK1/2, and then treated with increasing concentrations (0.1-30 µM) of Sup ODNs or control ODNs for up to 24 h in normal medium. Western blot analysis revealed that cells treated with 3 µM Sup ODNs reduced Akt phosphorylation (at both Ser473 and Thy308) and ERK1/2 phosphorylation compared to those treated with 3 µM control ODNs (Fig. 4A) . The effect of Sup ODNs was confirmed by a dose-dependent reduction of Akt and ERK1/2 phosphorylation or 3 h after administration ( Fig. 4B and C) . No such effect was observed in cells treated with control ODNs. Treatment with Sup ODNs tended to increase the level of expression of the tumor-suppressor gene p15
INK4b and p27
KIP1
, particularly at 18 and 24 h (Fig. 4A) . From 12 to 24 h, Sup ODNs reduced the expression of pRb, which acts as control checkpoint for the G1 phase of the cell cycle (Fig. 4A) . These findings suggest that G1 cell cycle arrest might be involved in the antiproliferative activity of Sup ODNs.
Effect of combining Sup ODNs with anticancer drugs.
To examine whether Sup ODNs might interact synergistically with various drugs currently approved for the treatment of NSCLC patients, A549 NSCLC cell line was cultured with increasing concentrations of Sup ODNs plus other third-generation anticancer drugs (including 5-FU, gemcitabine, paclitaxel, VNR and irinotecan) or platinum-containing drugs (carboplatin and cisplatin) for 72 h and the subsequent assessment of their effects on cell viability by using the MTT assay. Combining results from multiple dose-response curves enabled us to calculate CI. The experiment used a variable-ratio drug combination design that enabled the magnitude of synergy (or antagonism) between agents to be calculated independently for each data point. Table Ι shows that the mean CI value for each of the combinations, except the platinum-containing drugs, ranged from 0.43 to 0.78, indicating that adding Sup ODNs to third-generation conventional anticancer drugs synergistically (defined by CI <1.0) reduced the proliferation of A549 cells. Of these, 5-FU and VNR showed favorable outcomes when combined with Sup ODNs, therefore, we further analyzed the combination effects by using these drugs. Increasing amounts of Sup ODN plus 5-FU reduced cell viability in a dose-dependent manner (Fig. 5A) . Combining results from multiple dose-response curves and normalized isobolograms based on the method of Chou and Talalay are shown in Fig. 5B and C (21,22) . In the normalized isobologram, experimental data points, represented by dots located below, on or above the diagonal line, indicate synergism, additivity and antagonism, respectively. As shown in Fig. 5B and C, results from combining treatment of Sup ODNs plus 5-FU indicated a favorable outcome for synergism. Fig. 6A and B) . Western blot analysis revealed that Sup ODNs increase cleaved caspase-3, cleaved poly ADP ribose polymerase (PARP) and bax, and decrease bcl-xL that acts as pro-survival protein by inhibiting its apoptotic effect (Fig. 6C) .
Synergistic induction of apoptosis by Sup
Discussion
This study demonstrated that Sup ODNs inhibited A549 cell proliferation by reducing Akt and Erk1/2 phosphorylation and then increasing expression of cyclin-dependent kinase inhibitors (p15  INK4b and p27   KIP1 ), and increased sensitivity of cells to conventional anticancer drugs.
Sup ODNs inhibit inflammatory responses and prevent the development of inflammation-dependent cancer (9-11,14,15) . However, the current work is believed to be the first to document that Sup ODNs have a direct antiproliferative effect on cancer cell line. Studies involving ODNs with suppressive activity (but a different sequence than Sup ODNs) have reported that ODNs and plasmids containing telomere-derived TTAGGG sequence motifs induce apoptosis and cellular senescence via the ataxia-telangiectasia mutated (ATM) gene-p53-p21 and p16
INK4a -pRb pathways in malignant cells (23) (24) (25) (26) . Current results examine the antiproliferative effects of Sup ODNs on A549 NSCLC cell line (p16 INK4a -null but wild-type p53). Our results revealed that Sup ODNs did not increase the expression of p53 and p21 (Fig. 3A) . Thus, our data suggest that Sup ODNs induce G1 cell cycle arrest via different pathways.
The western blot analysis results shown in Fig. 3 (19) . Many human malignancies are characterized by inactivation of p16 INK4a or pRb, or the amplification of cyclin D1 or Cdk4 (27) . The A549 cell line used in the present work was null for p16
INK4a but wild-type for pRb. p21 and p27
KIP1 is a member of the Cip/Kip family of cyclin-dependent kinase inhibitors. These proteins inhibit kinase activities of pre-activated G1 cyclin E-Cdk2 and other cyclins (28) . pRb exists in three general forms: unphosphorylated, hypophosphorylated and hyperphosphorylated. Freshly synthesized pRb is unphosphorylated and is present during the G0 phase of the cell cycle. Hypophosphorylated pRb is present in contact-inhibited cells during early G1. Hyperphosphorylated pRb is inactive and is present in the late G1, S, G2 and M phases of the cell cycle (29) . These findings suggest that Sup ODNs induce G1 cell cycle arrest via the p15
INK4b and p27 KIP1 /pRb pathway rather than senescence via the ATM-p53-p21 or p16
INK4a -pRb pathways. We found that Sup ODNs decreased the activated form of Akt and ERK1/2 as a mechanism of increasing the expression of p15
INK4b and p27 KIP1 on A549 cells. As shown in Fig. 4 , the addition of Sup ODNs to cultured NSCLC cells decreased their accumulation of the activated form of the serine/threonine protein kinase Akt and ERK1/2 in a dose-dependent manner. Activated Akt phosphorylates a variety of proteins involved in critical cellular processes, including proliferation and survival (30, 31) . Moreover, the activated form of Akt has been linked to tumorigenesis and drug resistance in cancer cells, and correlates with poor prognosis in NSCLC (4,30,31) . Similarly ERK signaling also promotes cell proliferation, cell survival and metastasis. This pathway is aberrantly activated in cancer, and the ERK pathways have attracted intense research interests (6, 32) . Thus, these findings suggest that Sup ODNs may be of value in the therapy of lung cancer.
Although treatment with Sup ODNs as a stand-alone agent may slow the growth of A549 NSCLC cell line, chemotherapy of patients with advanced disease typically includes multiple agents (33) . Recent reports document that agents with specific molecular targets can be combined with conventional anticancer drugs to improve treatment of patients with advanced NSCLC (34, 35) . Thus, the potential benefit of administering Sup ODNs in combination with anticancer drugs was evaluated. As seen in Fig. 5 and Table I , Sup ODNs were found to synergize with several third-generation anticancer drugs, but not with platinumcontaining drugs.
In general, agents that target microtubules (such as paclitaxel and VNR) block cell growth by inhibiting mitosis, whereas topoisomerase inhibitors (such as irinotecan) and antimetabolites (such as 5-FU and gemcitabine) are characterized by S-phase-specific cytotoxicity and induce apoptosis and G1 cell cycle arrest (36, 37) . Although Sup ODNs also induced G1 cell cycle arrest (Figs. 2 and 3 ), their activity was synergistic when combined with topoisomerase inhibitors and anti-metabolites (Table I) . There are two possible explanations for this. First, topoisomerase inhibitors and antimetabolites cause DNA damage and then induce G1 cell cycle arrest via the ATM/p53/p21 pathway. This differs from the effect of Sup ODNs, which blocks the p15
KIP1
/pRb pathway (Figs. 3 and 4) . Second, Akt inhibits cell death pathways by directly phosphorylating and inactivating proteins involved in apoptosis (38) . As seen in Figs. 4 and 6, Sup ODNs decreased the activated form of Akt (phosphorylated Akt), and decreased expression of pro-survival protein (such as bcl-xL), leading to induce apoptosis. Moreover, Sup ODNs synergistically enhanced apoptosis when combined with other agents including VNR (Fig. 6) .
The anticancer effect of platinum-containing drugs depends on the ability to bind covalently to DNA and subsequently to modify the structure of the DNA. Such covalent interactions result in crosslinks between adjacent nucleobases that block DNA replication and transcription, and ultimately, cell division (39) . It is well known that platinum-containing drugs form preferably covalent bonds to the AG and GG sequences of DNA and ODNs (40, 41) . Therefore, we assume that cisplatin and carboplatin bound to Sup ODNs, which led to inhibition of effective delivery of Sup ODNs to target lesions, and thus resulting in no significant synergism for combination of platinum-containing drugs and Sup ODNs.
In conclusion, our results are believed to be the first to demonstrate that Sup ODNs have a direct anticancer effect, and increase the sensitivity of A549 NSCLC cells to conventional anticancer drugs by modifying the Akt and ERK1/2 pathway. Thus, Sup ODNs may become a novel therapeutic strategy for NSCLC patients. Studies to elucidate further the efficacy of Sup ODNs in animal models of lung cancer are planned.
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